CUSIP No. 45104P500
|
Page 2 of 7 Pages
|
1
|
NAME OF REPORTING PERSON
Merlin BioMed Private Equity Advisors, LLC (IRS No. 13-4178606)
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
OO
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
750,000
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
750,000
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
750,000
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.5%
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
OO
|
CUSIP No. 45104P500
|
Page 3 of 7 Pages
|
1
|
NAME OF REPORTING PERSON
Merlin Nexus III, L.P.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
OO
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
750,000
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
750,000
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
750,000
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.5%
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
PN
|
CUSIP No. 45104P500
|
Page 4 of 7 Pages
|
1
|
NAME OF REPORTING PERSON
Dominique Sémon
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
OO
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
750,000
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
750,000
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
750,000
|
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.5%
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
IN
|
ITEM 4.
|
Purpose of Transaction
|
ITEM 5
|
Interest in Securities of the Issuer
|
ITEM 7
|
Material to be Filed as Exhibits
|
Exhibit
|
Description
|
4.
|
August 11 Joint Letter, dated August 11, 2011, to the Board of Directors of the Issuer.
|
5. | August 11 Press Release, issued August 11, 2011. |
MERLIN BIOMED PRIVATE EQUITY INVESTORS, LLC | ||||
By: DOMINIQUE SÉMON, Managing Member | ||||
/s/ Dominique Sémon
|
||||
MERLIN NEXUS III, L.P.
|
||||
By: MERLIN NEXUS III, LLC., General Partner | ||||
/s/ Dominique Sémon
|
||||
Name: | Dominique Sémon | |||
Title: | Managing Member | |||
/s/ Dominique Sémon
|
||||
Name: | Dominique Sémon | |||
Exhibit
|
Description
|
1.
|
Joint Letter, dated July 28, 2011, to the Board of Directors of the Issuer.*
|
2.
|
Press Release, issued July 28, 2011.*
|
3.
|
Joint Filing Agreement, dated July 29, 2011, between Merlin BioMed Private Equity Advisors, LLC, Merlin Nexus III, L.P. and Dominique Sémon.*
|
4.
|
August 11 Joint Letter, dated August 11, 2011, to the Board of Directors of the Issuer.
|
5. | August 11 Press Release, issued August 11, 2011. |
Merlin Nexus III, L.P.
|
New Leaf Ventures II, L.P.
|
cc:
|
Anthony B. Evnin, Ph.D., Director
|